معرفی
Mark A Lemmon is the Alfred Gilman Professor of Pharmacology and Co-Director of the Yale Cancer Biology Institute at Yale School of Medicine. He previously served as George W. Raiziss Professor of Biochemistry and Biophysics and Chair at the University of Pennsylvania's Perelman School of Medicine. Currently, he chairs the Department of Pharmacology and leads research at the intersection of structural biology and cancer therapeutics.
- Department of Pharmacology, Yale School of Medicine
- Yale Cancer Biology Institute
- Abramson Family Cancer Research Institute (University of Pennsylvania)
Research Focus: Dr. Lemmon investigates receptor tyrosine kinase (RTK) signaling networks, particularly how mutations in EGFR and ALK cause cancer and drug resistance. His lab combines biochemical, structural, and computational approaches to develop predictive algorithms for mutation-driven oncogenic activation and therapeutic strategies.
Recent Work Trends: Current publications emphasize allosteric regulation of immune signaling receptors, differential inhibitor sensitivity in RTK mutants, and glycoproteomic analysis of immune checkpoints. Collaborations with clinical groups and computational scientists highlight translational applications.
Scientific Recognition:
- Fellow of the Royal Society (2016)
- Dorothy Crowfoot Hodgkin Award, Protein Society
- Stanley N. Cohen Biomedical Research Award, University of Pennsylvania
Key Collaborators: Dr. Lemmon works with Peter Klein (Xenopus research), Ravi Radhakrishnan (computational mutation prediction), and clinical groups at Yale and Penn. He chairs the Editorial Board of the Biochemical Journal and advises on Cell and Molecular Cell.
